Match!
Brett Glotzbecker
Harvard University
75Publications
14H-index
993Citations
Publications 78
Newest
#1Justin Cook Solle (Harvard University)
#2Sara Close (Harvard University)
Last.Shauna Curran (Harvard University)
view all 13 authors...
Introduction With rapidly increasing demand at academic medical centers, inpatient resource allocation is a critical focus. Patients receiving autologous stem cell transplant (ASCT) often face complicated discharges, requiring lengthy day of discharge teaching sessions from nurses and dietitians that may cause delays in discharge time. We queried if streamlining the complex discharge process by scheduling teaching appointments in advance would reduce unnecessary delays in discharge. Methods An i...
Source
#1Alissa J Cooper (Brigham and Women's Hospital)
#2Steven P. Keller (Brigham and Women's Hospital)H-Index: 4
Last.Chanu Rhee (Harvard University)H-Index: 15
view all 7 authors...
Rationale: There have been advances in both cancer and sepsis treatment over the past several decades, yet little is known about trends in sepsis-associated mortality in patients with versus withou...
Source
#1Elaine Xiang (Harvard University)
#2Jian Ni (Brigham and Women's Hospital)
Last.Anne M. McDonnell (Brigham and Women's Hospital)H-Index: 8
view all 6 authors...
IntroductionFor multiple myeloma patients who respond to primary therapy, autologous hematopoietic stem cell transplant (HSCT) is considered standard of care with high-dose melphalan for transplant candidates. There are now two different melphalan formulations available, including a propylene glycol containing (PG-MEL) product and a propylene glycol-free (PG-free MEL) product. Although considered bioequivalent, there remains limited literature directly evaluating the adverse events between the t...
Source
#1Clinton W. Lewis (Auckland City Hospital)
#2Haesook T. Kim (Harvard University)H-Index: 57
Last.Vincent T. Ho (Harvard University)H-Index: 71
view all 16 authors...
ABSTRACT fludarabine with intravenous busulfan at doses of 3.2 mg/kg (Flu/Bu1) or 6.4mg/kg (Flu/Bu2) Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a serious complication of hematopoietic stem cell transplantation (HCT) that is felt to be triggered, at least in part, by damage to the liver sinusoidal endothelium from cytotoxic conditioning regimens. Accordingly, the incidence of VOD/SOS after reduced-intensity conditioning (RIC) HCT is low compared with myeloablative...
Source
#1Matthew P. Cheng (Harvard University)H-Index: 10
#2Amanda E. Kusztos (Harvard University)H-Index: 3
Last.Francisco M. Marty (Harvard University)H-Index: 44
view all 10 authors...
3 CitationsSource
11607Background: Melphalan, remains the mainstay of conditioning for autologous hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and non-Hodgkin lymphoma (NHL) patients. Gast...
#1Houry Leblebjian (Harvard University)H-Index: 7
#2Megan Duperrault (Harvard University)
Last.David W. Dougherty (Harvard University)H-Index: 1
view all 10 authors...
e18225Background: With approvals across multiple cancer types and favorable toxicity profiles, oncologists may consider using immunotherapy (IMT) while their patients are hospitalized. Inpatient IM...
Source
#1Jackie Foster (National Marrow Donor Program)H-Index: 2
#2Heather Moore (National Marrow Donor Program)H-Index: 2
Last.Ellen M. Denzen (Center for International Blood and Marrow Transplant Research)H-Index: 11
view all 13 authors...
Hematopoietic cell transplantation (HCT) is a complex and potentially life-threatening treatment option for patients with hematologic malignant and non-malignant diseases. Advances have made HCT a potentially curative treatment option for patients 65 years of age and older (older patients), and patient education resources should be adapted to meet their needs. To better understand the information needs of older patients and their caregivers for HCT treatment decision-making, the National Marrow ...
Source
#1Sarah Nikiforow (Harvard University)H-Index: 18
#2Nancy Berliner (Brigham and Women's Hospital)H-Index: 38
Last.Joseph H. Antin (Harvard University)H-Index: 101
view all 15 authors...
Introduction HLH has historically been considered a pediatric disease. There are limited prospective data for adults with HLH, particularly on management during and outcomes after allogeneic HSCT. Following the CTN1204 study of HSCT in pediatric HLH, this retrospective analysis sets a benchmark for adult-onset HLH. Subjects We identified 20 patients, median 45yo (21-72), who underwent RIC HSCT for HLH since 2010. 5 (25%) had a malignancy, 3 (15%) a rheumatologic diagnosis, and 3 (15%) a viral pr...
Source
Source
12345678